Opus Genetics (IRD) Projected to Announce Quarterly Earnings on Wednesday

Opus Genetics (NASDAQ:IRD) is expected to be issuing its Q3 2026 results before the market opens on Wednesday, November 11th. Analysts expect Opus Genetics to announce earnings of ($0.14) per share and revenue of $1.55 million for the quarter. Investors can check the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 12, 2026 at 12:30 PM ET.

Opus Genetics (NASDAQ:IRD) last posted its earnings results on Thursday, August 6th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.02. The business had revenue of $0.76 million during the quarter, compared to analysts’ expectations of $2.63 million. On average, analysts expect Opus Genetics to post ($0.97) EPS for the current fiscal year and ($0.70) EPS for the next fiscal year.

Opus Genetics Stock Performance

Opus Genetics stock opened at $3.93 on Wednesday. The stock’s fifty day moving average is $4.46 and its two-hundred day moving average is $4.17. Opus Genetics has a 1-year low of $1.70 and a 1-year high of $7.07.

Insider Transactions at Opus Genetics

In related news, Director Fighting Blindness Foundation sold 556,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 30th. The stock was sold at an average price of $4.96, for a total transaction of $2,757,760.00. Following the transaction, the director owned 3,236,171 shares in the company, valued at $16,051,408.16. This trade represents a 14.66% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Robert E. Gagnon sold 28,000 shares of the stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $4.54, for a total value of $127,120.00. Following the completion of the sale, the chief financial officer directly owned 556,375 shares of the company’s stock, valued at $2,525,942.50. The trade was a 4.79% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 645,547 shares of company stock worth $3,103,375. 11.70% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on IRD. TD Cowen initiated coverage on Opus Genetics in a report on Wednesday, July 29th. They issued a “buy” rating on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Opus Genetics in a research note on Thursday, October 15th. Royal Bank Of Canada lowered their price target on Opus Genetics from $10.00 to $9.00 and set an “outperform” rating for the company in a report on Friday, August 7th. BTIG Research reaffirmed a “buy” rating and issued a $12.00 price target on shares of Opus Genetics in a report on Wednesday, September 9th. Finally, Wall Street Zen upgraded shares of Opus Genetics from a “sell” rating to a “hold” rating in a research note on Sunday, October 4th. One analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $12.71.

About Opus Genetics

Opus Genetics, Inc is a clinical-stage biotechnology company focused on developing gene therapies for inherited retinal diseases (IRDs), a group of rare genetic disorders that can cause progressive vision loss and blindness. The company’s research is aimed at addressing the underlying genetic causes of these conditions rather than treating only their symptoms.

Its pipeline includes investigational ophthalmic gene therapies designed for specific IRD-causing mutations, including programs targeting conditions associated with the NR2E3 and BEST1 genes.